---
document_datetime: 2025-12-02 05:14:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-teva.html
document_name: dimethyl-fumarate-teva.html
version: success
processing_time: 0.106414
conversion_datetime: 2025-12-23 21:17:42.538048
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dimethyl fumarate Teva

[RSS](/en/individual-human-medicine.xml/67629)

##### Revoked

This medicine's authorisation has been revoked

dimethyl fumarate Medicine Human Revoked

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dimethyl fumarate Teva](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 13 December 2023, the European Commission revoked the marketing authorisation for Dimethyl fumarate Teva (dimethyl fumarate) in the European Union (EU). Dimethyl fumarate Teva was a generic medicine of Tecfidera. The marketing authorisation holder for the medicine was TEVA GmbH.

The revocation of the marketing authorisation was necessary in order to implement the judgment of the Court of Justice of 16 March 2023 in Commission and Others v Pharmaceutical Works Polpharma, Cases C-438/21 P to C-440/21 P.

It follows from that judgment that the marketing authorisation for Dimethyl fumarate Teva was submitted at a point in time when the regulatory data protection period of the reference product (Tecfidera) had not expired. Further information in relation to the revocation of Dimethyl fumarate Teva may be found in the Commission Implementing Decision revoking the marketing authorisation, which is available on the Union Register of medicinal products for human use. Dimethyl fumarate Teva was granted marketing authorisation in the EU on 12 December 2022 for treatment of relapsing remitting multiple sclerosis (RRMS).

The European Public Assessment Report (EPAR) for Dimethyl fumarate Teva is updated to indicate that the marketing authorisation is no longer valid.

Dimethyl fumarate Teva: EPAR - Medicine overview

Reference Number: EMEA/H/C/005963

English (EN) (213.27 KB - PDF)

**First published:** 21/12/2022

**Last updated:** 22/12/2023

[View](/en/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-695)

български (BG) (264.07 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/bg/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_bg.pdf)

español (ES) (214.51 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/es/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_es.pdf)

čeština (CS) (248.51 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/cs/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_cs.pdf)

dansk (DA) (209.89 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/da/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_da.pdf)

Deutsch (DE) (216.08 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/de/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_de.pdf)

eesti keel (ET) (193.81 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/et/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (270.75 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/el/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_el.pdf)

français (FR) (215.62 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/fr/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (235.89 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/hr/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_hr.pdf)

italiano (IT) (207.12 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/it/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (261.64 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/lv/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (240.4 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/lt/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_lt.pdf)

magyar (HU) (244.74 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/hu/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_hu.pdf)

Malti (MT) (252.41 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/mt/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (214.09 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/nl/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_nl.pdf)

polski (PL) (245.66 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/pl/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_pl.pdf)

português (PT) (212.96 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/pt/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_pt.pdf)

română (RO) (245.66 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/ro/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (241.87 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sk/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (234.17 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sl/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_sl.pdf)

Suomi (FI) (206.12 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/fi/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_fi.pdf)

svenska (SV) (207.39 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sv/documents/overview/dimethyl-fumarate-teva-epar-medicine-overview_sv.pdf)

Dimethyl fumarate Teva: EPAR - Risk management plan summary

English (EN) (456.49 KB - PDF)

**First published:** 21/12/2022

**Last updated:** 22/12/2023

[View](/en/documents/rmp-summary/dimethyl-fumarate-teva-epar-risk-management-plan-summary_en.pdf)

## Product information

Dimethyl fumarate Teva: EPAR - Product information

English (EN) (2.03 MB - PDF)

**First published:** 21/12/2022

**Last updated:** 22/12/2023

[View](/en/documents/product-information/dimethyl-fumarate-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-790)

български (BG) (2.34 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/bg/documents/product-information/dimethyl-fumarate-teva-epar-product-information_bg.pdf)

español (ES) (1.79 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/es/documents/product-information/dimethyl-fumarate-teva-epar-product-information_es.pdf)

čeština (CS) (1.95 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/cs/documents/product-information/dimethyl-fumarate-teva-epar-product-information_cs.pdf)

dansk (DA) (1.71 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/da/documents/product-information/dimethyl-fumarate-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.87 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/de/documents/product-information/dimethyl-fumarate-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.72 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/et/documents/product-information/dimethyl-fumarate-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.57 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/el/documents/product-information/dimethyl-fumarate-teva-epar-product-information_el.pdf)

français (FR) (1.87 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/fr/documents/product-information/dimethyl-fumarate-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.92 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/hr/documents/product-information/dimethyl-fumarate-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.72 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/is/documents/product-information/dimethyl-fumarate-teva-epar-product-information_is.pdf)

italiano (IT) (1.86 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/it/documents/product-information/dimethyl-fumarate-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (2.09 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/lv/documents/product-information/dimethyl-fumarate-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.11 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/lt/documents/product-information/dimethyl-fumarate-teva-epar-product-information_lt.pdf)

magyar (HU) (2.03 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/hu/documents/product-information/dimethyl-fumarate-teva-epar-product-information_hu.pdf)

Malti (MT) (2.13 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/mt/documents/product-information/dimethyl-fumarate-teva-epar-product-information_mt.pdf)

Nederlands (NL) (1.78 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/nl/documents/product-information/dimethyl-fumarate-teva-epar-product-information_nl.pdf)

norsk (NO) (1.72 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/no/documents/product-information/dimethyl-fumarate-teva-epar-product-information_no.pdf)

polski (PL) (2.15 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/pl/documents/product-information/dimethyl-fumarate-teva-epar-product-information_pl.pdf)

português (PT) (1.74 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/pt/documents/product-information/dimethyl-fumarate-teva-epar-product-information_pt.pdf)

română (RO) (2.21 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/ro/documents/product-information/dimethyl-fumarate-teva-epar-product-information_ro.pdf)

slovenčina (SK) (1.91 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sk/documents/product-information/dimethyl-fumarate-teva-epar-product-information_sk.pdf)

slovenščina (SL) (1.87 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sl/documents/product-information/dimethyl-fumarate-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.8 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/fi/documents/product-information/dimethyl-fumarate-teva-epar-product-information_fi.pdf)

svenska (SV) (1.73 MB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sv/documents/product-information/dimethyl-fumarate-teva-epar-product-information_sv.pdf)

12/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dimethyl fumarate Teva: EPAR - All authorised presentations

English (EN) (82.56 KB - PDF)

**First published:** 21/12/2022

**Last updated:** 22/12/2023

[View](/en/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-514)

български (BG) (156.36 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/bg/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (91.92 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/es/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (92.63 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/cs/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (80.06 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/da/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (91.56 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/de/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (84.3 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/et/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (120.95 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/el/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (88.92 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/fr/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (98.55 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/hr/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (91.2 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/is/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (87.12 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/it/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (116.96 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/lv/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (114.7 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/lt/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (108.94 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/hu/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (108.08 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/mt/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (93.75 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/nl/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (71.05 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/no/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (107.35 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/pl/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (86.34 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/pt/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (111.1 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/ro/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (103.43 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sk/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (95.38 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sl/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (80.68 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/fi/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (74.12 KB - PDF)

**First published:**

21/12/2022

**Last updated:**

22/12/2023

[View](/sv/documents/all-authorised-presentations/dimethyl-fumarate-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dimethyl fumarate Teva Active substance dimethyl fumarate International non-proprietary name (INN) or common name dimethyl fumarate Therapeutic area (MeSH)

- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis

Anatomical therapeutic chemical (ATC) code L04AX07

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

## Authorisation details

EMA product number EMEA/H/C/005963

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva GmbH

Graf-Arco-Straße 3

Opinion adopted 13/10/2022 Marketing authorisation issued 12/12/2022 Revocation of marketing authorisation 13/12/2023

## Assessment history

## Initial marketing authorisation documents

Dimethyl fumarate Teva: EPAR - Public Assessment Report

English (EN) (4.37 MB - PDF)

**First published:** 21/12/2022

**Last updated:** 22/12/2023

[View](/en/documents/assessment-report/dimethyl-fumarate-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dimethyl fumarate Teva

Adopted

Reference Number: EMA/CHMP/790837/2022

English (EN) (161.87 KB - PDF)

**First published:** 14/10/2022

**Last updated:** 22/12/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dimethyl-fumarate-teva_en.pdf)

#### News on Dimethyl fumarate Teva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) 14/10/2022

**This page was last updated on** 22/12/2023

## Share this page

[Back to top](#main-content)